9/25/24 20:54 | 9/23/24 | LGND | Health | Drug | Pharmaceutical Preparations | Reardon Andrew | FL | O | CLO,Secr | M.d | 105 | 52.27 | 0 | 2 | 10 | 23 | D | | | | | | | | | | | | | | |
9/25/24 20:54 | 9/23/24 | LGND | Health | Drug | Pharmaceutical Preparations | Reardon Andrew | FL | O | CLO,Secr | S.d | -199 | 99.60 | 0 | -2 | -8 | 23 | D | | | | | | | | | | | | | | |
9/24/24 19:41 | 9/20/24 | LGND | Health | Drug | Pharmaceutical Preparations | Espinoza Octavio | FL | O | CFO | S | -133 | 103.94 | 0 | -1 | -5 | 25 | D | | | | | | | | | | | | | | |
9/24/24 19:41 | 9/20/24 | LGND | Health | Drug | Pharmaceutical Preparations | Korenberg Matthew E | FL | O | P,COO | M.dm | 764 | 51.80 | 0 | 15 | 41 | 51 | D | | | | | | | | | | | | | | |
9/24/24 19:41 | 9/20/24 | LGND | Health | Drug | Pharmaceutical Preparations | Korenberg Matthew E | FL | O | P,COO | S.dm | -1,642 | 102.35 | 0 | -16 | -24 | 51 | D | | | | | | | | | | | | | | |
9/19/24 17:50 | 9/17/24 | LGND | Health | Drug | Pharmaceutical Preparations | Espinoza Octavio | FL | O | CFO | M.d | 118 | 79.63 | 0 | 1 | 6 | 26 | D | | | | | | | | | | | | | | |
9/18/24 19:55 | 9/16/24 | LGND | Health | Drug | Pharmaceutical Preparations | Korenberg Matthew E | FL | O | P,COO | M.d | 338 | 58.49 | 0 | 6 | 12 | 52 | D | | | | | | | | | | | | | | |
8/30/24 21:00 | 8/28/24 | LGND | Health | Drug | Pharmaceutical Preparations | Espinoza Octavio | FL | O | CFO | M.d | 50 | 66.52 | 0 | 1 | 3 | 24 | D | | | | | | | | | | | | | | |
8/30/24 20:56 | 8/28/24 | LGND | Health | Drug | Pharmaceutical Preparations | Reardon Andrew | FL | O | CLO,Secr | M.d | 78 | 52.27 | 0 | 2 | 7 | 23 | D | | | | | | | | | | | | | | |
8/30/24 20:56 | 8/28/24 | LGND | Health | Drug | Pharmaceutical Preparations | Reardon Andrew | FL | O | CLO,Secr | S.d | -160 | 106.39 | 0 | -2 | -6 | 23 | D | | | | | | | | | | | | | | |
8/26/24 20:15 | 8/22/24 | LGND | Health | Drug | Pharmaceutical Preparations | Korenberg Matthew E | FL | O | P,COO | S.m | -1,986 | 105.34 | 0 | -19 | -28 | 50 | D | | | | | | | | | | | | | | |
8/13/24 17:21 | 8/9/24 | LGND | Health | Drug | Pharmaceutical Preparations | Korenberg Matthew E | FL | O | P,COO | S | -1,797 | 98.50 | 0 | -18 | -21 | 68 | D | | | | | | | | | | | | | | |
8/9/24 17:52 | 8/8/24 | LGND | Health | Drug | Pharmaceutical Preparations | Davis Todd C | FL | DO | CEO | P | 243 | 97.39 | 0 | 3 | 2 | 123 | D | | | | | | | | | | | | | | |
5/17/24 20:00 | 5/9/24 | LGND | Health | Drug | Pharmaceutical Preparations | Gray Nancy Ryan | FL | D | | S | -78 | 83.20 | 0 | -1 | -14 | 6 | D | | | | | | | | | | | | | | |
5/17/24 19:59 | 5/15/24 | LGND | Health | Drug | Pharmaceutical Preparations | Espinoza Octavio | FL | O | CFO | S.dm | -1,147 | 86.26 | 0 | -13 | -36 | 23 | D | | | | | | | | | | | | | | |
5/17/24 19:59 | 5/17/24 | LGND | Health | Drug | Pharmaceutical Preparations | Espinoza Octavio | FL | O | CFO | M.d | 385 | 55.71 | 0 | 7 | 42 | 23 | D | | | | | | | | | | | | | | |
5/15/24 19:34 | 5/13/24 | LGND | Health | Drug | Pharmaceutical Preparations | Korenberg Matthew E | FL | O | P,COO | S.m | -1,496 | 84.99 | 0 | -18 | -17 | 86 | D | | | | | | | | | | | | | | |
5/13/24 17:32 | 5/9/24 | LGND | Health | Drug | Pharmaceutical Preparations | Reardon Andrew | FL | O | GC, | M.d | 523 | 52.27 | 0 | 10 | 82 | 22 | D | | | | | | | | | | | | | | |
5/13/24 17:32 | 5/9/24 | LGND | Health | Drug | Pharmaceutical Preparations | Reardon Andrew | FL | O | GC, | S.d | -830 | 83.04 | 0 | -10 | -31 | 22 | D | | | | | | | | | | | | | | |
5/2/24 18:07 | 4/30/24 | LGND | Health | Drug | Pharmaceutical Preparations | Aryeh Jason | FL | D | | M.d | 126 | 52.30 | 0 | 2 | 2 | 133 | D | | | | | | | | | | | | | | |
4/26/24 18:35 | 4/24/24 | LGND | Health | Drug | Pharmaceutical Preparations | Kozarich John W | FL | D | | M.d | 114 | 39.35 | 0 | 3 | 7 | 43 | D | | | | | | | | | | | | | | |
3/27/24 17:47 | 3/25/24 | LGND | Health | Drug | Pharmaceutical Preparations | Davis Todd C | FL | DO | CEO | M.d | 919 | 57.39 | 0 | 16 | 15 | 120 | D | | | | | | | | | | | | | | |
3/7/24 13:27 | 3/5/24 | LGND | Health | Drug | Pharmaceutical Preparations | Sabba Stephen L | NY | D | | M.d | 0 | 0.00 | 0 | 3 | 11 | 29 | D | | | | | | | | | | | | | | |
3/7/24 13:27 | 3/5/24 | LGND | Health | Drug | Pharmaceutical Preparations | Sabba Stephen L | NY | D | | S.d | -141 | 74.30 | 0 | -2 | -6 | 29 | D | | | | | | | | | | | | | | |
3/6/24 17:28 | 3/5/24 | LGND | Health | Drug | Pharmaceutical Preparations | Aryeh Jason | CA | D | | M.d | 114 | 39.35 | 0 | 3 | 2 | 131 | D | | | | | | | | | | | | | | |
2/29/24 18:50 | 2/28/24 | LGND | Health | Drug | Pharmaceutical Preparations | Espinoza Octavio | CA | O | CFO | M.d | 72 | 56.62 | 0 | 1 | 4 | 30 | D | | | | | | | | | | | | | | |
2/29/24 18:50 | 2/28/24 | LGND | Health | Drug | Pharmaceutical Preparations | Espinoza Octavio | CA | O | CFO | S.d | -12 | 88.46 | 0 | 0 | 0 | 30 | D | | | | | | | | | | | | | | |
9/25/23 16:44 | 9/22/23 | LGND | Health | Drug | Pharmaceutical Preparations | Davis Todd C | CA | DO | CEO | P | 238 | 59.38 | 0 | 4 | 6 | 73 | D | | | | | | | | | | | | | | |
5/18/23 17:18 | 5/16/23 | LGND | Health | Drug | Pharmaceutical Preparations | Kozarich John W | CA | D | | S | -343 | 77.20 | 0 | -4 | -10 | 38 | D | | | | | | | | | | | | | | |
5/12/23 15:43 | 5/10/23 | LGND | Health | Drug | Pharmaceutical Preparations | Sabba Stephen L | NY | D | | M.d | 0 | 0.00 | 0 | 6 | 33 | 26 | D | | | | | | | | | | | | | | |
5/12/23 15:43 | 5/10/23 | LGND | Health | Drug | Pharmaceutical Preparations | Sabba Stephen L | NY | D | | S.d | -494 | 77.13 | 0 | -6 | -20 | 26 | D | | | | | | | | | | | | | | |
5/10/23 19:15 | 5/8/23 | LGND | Health | Drug | Pharmaceutical Preparations | Kozarich John W | CA | D | | M.d | 121 | 18.82 | 0 | 6 | 18 | 42 | D | | | | | | | | | | | | | | |
5/10/23 19:15 | 5/8/23 | LGND | Health | Drug | Pharmaceutical Preparations | Kozarich John W | CA | D | | S.d | -491 | 76.56 | 0 | -6 | -13 | 42 | D | | | | | | | | | | | | | | |
3/28/23 17:00 | 3/24/23 | LGND | Health | Drug | Pharmaceutical Preparations | Reardon Andrew | CA | O | See Rema | S | -21 | 69.92 | 0 | 0 | -2 | 16 | D | | | | | | | | | | | | | | |
12/20/22 18:36 | 12/16/22 | LGND | Health | Drug | Pharmaceutical Preparations | Higgins John L | CA | D | | S | -619 | 61.87 | 0 | -10 | -2 | 423 | D | | | | | | | | | | | | | | |
12/14/22 17:00 | 12/12/22 | LGND | Health | Drug | Pharmaceutical Preparations | Higgins John L | CA | D | | M.d | 256 | 12.78 | 0 | 20 | 5 | 433 | D | | | | | | | | | | | | | | |
11/21/22 19:04 | 11/17/22 | LGND | Health | Drug | Pharmaceutical Preparations | Higgins John L | CA | DO | CEO | S.d | -783 | 78.32 | 0 | -10 | -2 | 427 | D | | | | | | | | | | | | | | |
11/21/22 19:04 | 11/18/22 | LGND | Health | Drug | Pharmaceutical Preparations | Higgins John L | CA | DO | CEO | M.d | 128 | 12.78 | 0 | 10 | 2 | 427 | D | | | | | | | | | | | | | | |
11/10/22 16:30 | 11/9/22 | LGND | Health | Drug | Pharmaceutical Preparations | Espinoza Octavio | CA | O | CFO | S | -128 | 75.64 | 0 | -2 | -16 | 9 | D | | | | | | | | | | | | | | |
9/22/22 20:32 | 9/16/22 | LGND | Health | Drug | Pharmaceutical Preparations | Higgins John L | CA | DO | CEO | S.a | -88 | 88.06 | 0 | -1 | 0 | 366 | D | | | | | | | | | | | | | | |
9/16/22 19:49 | 9/15/22 | LGND | Health | Drug | Pharmaceutical Preparations | Higgins John L | CA | DO | CEO | S.m | -448 | 89.61 | 0 | -5 | -1 | 364 | D | | | | | | | | | | | | | | |
5/13/22 19:05 | 5/13/22 | LGND | Health | Drug | Pharmaceutical Preparations | Foehr Matthew W | CA | O | P,COO | P | 207 | 82.76 | 0 | 3 | 1 | 173 | D | | | | | | | | | | | | | | |
5/10/22 17:33 | 5/9/22 | LGND | Health | Drug | Pharmaceutical Preparations | Higgins John L | CA | DO | CEO | M.d | 175 | 21.92 | 0 | 8 | 2 | 349 | D | | | | | | | | | | | | | | |
3/1/22 16:34 | 2/28/22 | LGND | Health | Drug | Pharmaceutical Preparations | Kozarich John W | CA | D | | M.d | 92 | 12.53 | 0 | 7 | 22 | 41 | D | | | | | | | | | | | | | | |
3/1/22 16:34 | 2/28/22 | LGND | Health | Drug | Pharmaceutical Preparations | Kozarich John W | CA | D | | S.d | -93 | 102.62 | 0 | -1 | -2 | 41 | D | | | | | | | | | | | | | | |